Pregabalin vs gabapentin in the treatment of neuropathic pain in cancer patients Review article

Article Sidebar

Requires Subscription PDF (Język Polski)
Purchase article

Published: Mar 31, 2022
DOI: https://doi.org/10.24292/01.MF.0122.7
Keywords:
neuropathic pain, causes of neuropathic pain, neuropathic pain in cancer patients, pharmacotherapy of neuropathic pain, gabapentin, pregabalin – pharmacokinetics, pharmacodynamics, differences

Main Article Content

Małgorzata Malec-Milewska
Poradnia Leczenia Bólu, Klinika Anestezjologii i Intensywnej Terapii, Samodzielny Publiczny Szpital Kliniczny im. prof. W. Orłowskiego, Centrum Medycznego Kształcenia Podyplomowego

Abstract

Neuropathic pain affects an average of 7–10% of the population and is more often in elderly people and in women. It is a chronic pathological pain, resistant to analgesics from the first step of the analgesic ladder (paracetamol, metamizole, non-steroidal anti-inflammatory drugs). Neuropathic pain may be caused by: infectious diseases, trauma, ischemia, metabolic diseases, neurological diseases, toxic, consequences of damage to the nervous system resulting from the treatment of neoplastic disease, pressure, inflammation, as well as deficiencies. The American Academy of Neurology, Special Interest Group on Neuropathic Pain, and the European Federation of Neurological Societies recommend gabapentin/pregabalin and antidepressants as first choice in the treatment of neuropathic pain. In neuropathic pain accompanying neoplastic disease, due to its mixed nature, i.e., the coexistence of receptor pain, opioid analgesics are always used in the treatment: tramadol for moderate pain and strong opioids for high  pain. The following article describes the differences in the pharmacokinetics and pharmacodynamics of gabapentin and pregabalin.

Article Details

How to Cite
Malec-Milewska, M. (2022). Pregabalin vs gabapentin in the treatment of neuropathic pain in cancer patients. Medycyna Faktow (J EBM), 15(1(54), 50-55. https://doi.org/10.24292/01.MF.0122.7
Issue
Vol 15 No 1(54) (2022)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Treede RD, JensenTS, Campbell JN et al. Redefinition of neuropathic pain and a grading system for clinical use consensus statement on clinical and research diagnostic criteria. Neurology. 2008; 70: 1630-5.
2. Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018; 70: 315-47.
3. Malec-Milewska M, Sękowska A. Dekalog diagnostyki i leczenia bólu neuropatycznego. ITEM Publ. 2020.
4. Kocot-Kępska M, Mańka-Matłok M. Miejsce pregabaliny i gabapentyny w leczeniu chorych z bólem neuropatycznym. Ból. 2020; 21(3): 11-23.
5. Finnerup NB, Attal N, Haroutoumian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73.
6. Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Revue Neurol (Paris). 2019; 175: 46-50.
7. Szczudlik A, Dobrogowski J, Wordliczek J et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part two. Neurol Neurochir Pol. 2014; 48: 262-71.
8. Eckhardt K, Ammon S, Hofmann U et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000; 91(1): 185-91.
9. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661-9.
10. Sękowska A, Malec-Milewska M. Leczenie bólu neuropatycznego – stan wiedzy na rok 2019. Medical Education, Warszawa 2019.
11. Charakterystyka produktu leczniczego gabapentyna.
12. Charakterystyka produktu leczniczego pregabalina.
13. Derry S, Bell RF, Straube S. et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1(1): CD007076.
14. Wiffen PJ, Derry S, Bell RF. at al. Gabapentin of chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6(6): CD007938.
15. Arnold LM, McCarberg BH, Clair AG et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia and fibromyalgia. Postgrad Med. 2017; 129(8): 921-33.
16. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Paliat Care. 2018; 3(4): 108-17.
17. Zhang M, Gao CX, Ma KT et al. Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Post herpetic Neuralgia from Randomized Controlled Trials. Biomed Res Int. 2018; 4: 7474207.
18. Wiffen PJ, Derry S, Bell RF et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6(6): CD007938.
19. Moisset X, Bouhassira D, Avez Couturier J et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue Neurol (Paris). 2020; 176(5): 325-52.
20. Gruver Ch, Guthmiller KB. Postherpetic Neuralgia. StartPearls, Treasure Island (FL). 2021.
21. Gross GE, Eisert L, Doerr HW et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. Journal of Society Dermatol. 2019: 55-77.
22. Malec-Milewska, Zajączkowska R, Woroń J. Pacjent z bólem neuropatycznym – leczenie pierwszego i drugiego wyboru. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Wiedza w kieszeni. Ból. Termedia, Poznań 2020: 359-78.
23. Zajączkowska R, Mika-Kula J, Leppert W et al. Mirogabalin: a novel selective ligand for the alfa-2delta calcium channel submit. Pharmaceuticals. 2021; 14(2): 112.